AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03881956 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health-promoting lifestyle education program
Description: The intervention group were included in the health-promoting lifestyle education program. The education program consisted of three 45-min sessions, which included a face-to-face lecture with the dissemination and presentation of written and visual materials. Each participant in the intervention group was given the Health-Promoting Lifestyle Booklet and the Diary of a Woman with GDM card. The booklet features all of the health-promoting practices (self-monitoring of blood glucose, nutrition, physical activity, stress, sleeping, smoking, self-care and breastfeeding). The Diary of a Woman with GDM card features the daily program that women should follow (the hours for main meals and snacks, insulin hours, etc.). The education and counseling were maintained through follow-up via phone for intervention group.
Study NCT00942435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: oral
Study NCT00942435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mechanical prophylaxis
Description: The investigator will determine the method of mechanical prophylaxis
Study NCT00839592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study NCT00839592 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electroacupuncture
Description: Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Study NCT02203214 — intervention group
Intervention type: DEVICE
Intervention: Ligamys
Description: All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
Study NCT04166448 — intervention group
Intervention type: OTHER
Intervention: Fetal MRI
Description: The MRI examination added by this research, without injection or sedation, induces no risk for the mother as for the fetus(es)
Study NCT03155321 — intervention group
Intervention type: OTHER
Intervention: It's an observational study - no intervention is planned
Description: No intervention is planned
Study NCT01043835 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted gastrectomy
Description: A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
Study NCT01043835 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open gastrectomy
Description: Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
Study NCT01340768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: One 100 mg tablet taken orally once daily
Study NCT01340768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfonylurea
Description: Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
Study NCT01340768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
Study NCT01340768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
Study NCT03591523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative MR angiography
Description: Quantitative MR angiography: A standard axial 3-dimensional time-of-flight (TOF) MRA of intracranial and cervical arteries will be obtained. Then, the acquired images will be transmitted to the workstation to reconstruct 3D surface-rendered vessel images. After determining optimal perpendicular scan plane and setting the baseline coordinates , retrospectively gated, fast 2-dimensional phase-contrast sequence will be performed. Velocity encoding will be automatically adjusted by NOVA software.
Study NCT00405054 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MK0457
Description: IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
Study NCT00548626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple needle
Description: Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
Study NCT03591523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex sonography
Description: Duplex sonography of cervical arteries will be performed using 5 - 12 MHz linear duplex probe and transcranial color-coded duplex sonography will be performed using 2 - 5 MHz transcranial duplex probe. Peak systolic velocity, end diastolic celocity, mean blood flow velocity and arterial diameter will be measured with automatic calculation of blood flow velocity in each arterial segment.
Study NCT00555360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HITCM+CP
Description: Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
Study NCT00555360 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HITCM only
Description: Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
Study NCT03884452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Tablets taken orally once daily in the morning
Study NCT03338816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givosiran
Description: Givosiran by SC
Study NCT03884452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Tablets taken orally once daily in the morning or evening
Study NCT03884452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Tablet taken orally once daily in the morning or evening
Study NCT03884452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Ezetimibe
Description: Tablets taken orally once daily in the morning or evening
Study NCT00437840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809
Description: GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
Study NCT03338816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Givosiran
Description: Givosiran by SC
Study NCT03338816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (normal saline \[0.9% NaCl\]) by SC
Study NCT03338816 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (normal saline \[0.9% NaCl\]) by SC
Study NCT02331745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor
Description: Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
Study NCT02331745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
Study NCT02331745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
Study NCT00437840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive single oral dose of matching placebo tablet to GSK598809.
Study NCT00801099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/Clavulanic Acid
Description: single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
Study NCT03506984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Threshold Inspiration Muscle Training Device
Description: Threshold based trainer is a small handled device.It includes a mouthpiece and a calibrated spring loaded valve. The valve control a constant inspiratory pressure training load and the patient must generate a suffient inspiratory pressure in order for the inspiratory valve to be opened and allow the air to be inhaled. The amount of resistance can be adjusted by varying the compression of the spring-loaded valve. Adjustment from 9cmH2o to 41cmH2o.
Study NCT03506984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Bicycle Ergometer
Description: Electronic Bicycle equipped with electronic break, display screen, adjustable seat, handle bar and foot straps will be used in High interval intensity training.
Study NCT00941148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargin
Study NCT00941148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH insulin
Study NCT00941148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Study NCT00941148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin (2000 mg/day)
Study NCT02845765 — intervention group
Intervention type: DEVICE
Intervention: Dynamic Vessel Analyzer (DVA)
Study NCT02845765 — intervention group
Intervention type: DRUG
Intervention: Phosphodiesterase type 5 Inhibitor (PDE5I)
Study NCT04790838 — intervention group
Intervention type: DRUG
Intervention: Test
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04790838 — intervention group
Intervention type: DRUG
Intervention: Reference
Description: 2 inhalations of Test and Reference product in each study period
Study NCT04259463 — intervention group
Intervention type: PROCEDURE
Intervention: Third molars extraction
Description: Third molars extractions with concious sedation or general anesthesia
Study NCT02269163 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immune Globulin Intravenous
Description: Gammargard, Gammaplex,Gamunex, or Octogam IGIV Product
Study NCT02269163 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prometic's Immune Globulin Intravenous 10%
Description: Liquid formulation of Prometic Immune Globulin Intravenous 10% (human) in 50 mL vials containing 100 mg/mL of immunoglobulin G (IgG)
Study NCT02753491 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational short interview
Description: New designed motivational short interview model
Study NCT02440022 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lutonix DCB
Study NCT02440022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Balloon Angioplasty Catheter
Study NCT02440022 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Transluminal Angiography
Description: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.
Study NCT02440022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angiography
Description: Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored.
Study NCT02843594 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LEEP intervention
Description: Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
Study NCT02843594 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Phaco Control
Study NCT04413864 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration
Description: Assigned Interventions:~* Blood samples collection at inclusion (D0) and follow-up visits (D2, D7 and M6)~* CAM-ICU scores during ICU hospitalisation, neurological questionnaires at M6 (GOAT, GOSE, MOCA, Barthel Index, PTSD, GDS, Rankin score, HADS)
Study NCT02252718 — intervention group
Intervention type: OTHER
Intervention: Stool Assessment
Description: After passing a stool by the child participating in the study, within a short-time interval (\<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition.
Study NCT01996943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethanol
Description: 6% volume/volume ethanol in 0.45% saline solution.
Study NCT01996943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo with be 0.45% saline solution (half normal saline).
Study NCT00001258 — intervention group
Intervention type: DRUG
Intervention: Oxygen-15 Water
Study NCT03381781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2,d1-5,ivgtt,28days as a duration
Study NCT03381781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: 0.16mg/kg,d1-5,ivgtt,28days as a duration
Study NCT03381781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 15mg/m\^2,hypodermic injection,q12h,d1-7
Study NCT01581372 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist care
Description: Pharmacist prescribing, education, drug management
Study NCT02402569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 32 channels Deep Brain Stimulator
Study NCT01582867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARTIS hemodialysis system
Description: Software versions:~Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01
Study NCT04819581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-103
Description: lidocaine topical system 5.4%
Study NCT04819581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZTlido
Description: lidocaine topical system 1.8%
Study NCT03371927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SINC Feeding Protocol
Description: Safe individualized nipple-feeding competence protocol for premature infants
Study NCT01697904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration of oxygen during newborn resuscitation in delivery room
Study NCT01697904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titration of oxygen during newborn resuscitation in delivery room
Study NCT00635440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)
Description: Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
Study NCT00635440 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)
Description: Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
Study NCT04203940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cyanoacryale
Description: mesh fixation was done using dots of N-butyl 2-cyanoacrylate tissue glue
Study NCT04203940 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture
Description: mesh fixation was done with polypropylene 2/0 sutures
Study NCT04054102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot and tDCS on-line
Description: Combined transcranial direct current stimulation(tDCS) on-line and upper extremity rehabilitation robot for 5 times a week for 4 weeks
Study NCT04054102 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Robot and sham tDCS
Description: Combined sham tDCS and upper extremity rehabilitation robot for 5 times a week for 4 weeks
Study NCT01914783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrafine particles
Description: exposure to ultrafine particles
Study NCT01914783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrafine particles and ozone
Description: exposure to ultrafine particles and ozone
Study NCT01914783 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: clean air
Description: Exposure to clean air.
Study NCT02321683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taperloc
Description: Femoral stem with electrochemical deposition of hydroxyapatite
Study NCT02321683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taperloc
Description: Femoral stem with electrochemical deposition of hydroxyapatite
Study NCT01635036 — intervention group
Intervention type: DEVICE
Intervention: In-vitro fertilization using Eeva
Description: Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
Study NCT03198104 — intervention group
Intervention type: DEVICE
Intervention: MRI
Study NCT00778713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Study NCT00778713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
Study NCT02629536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Description: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Study NCT02629536 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Description: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
Study NCT01611298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus
Description: Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.~Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).~Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection.
Study NCT04324086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide with XP-endo Finisher file
Description: XP-endo Finisher files (FKG Dentaire, La Chaux-de-Fonds, Switzerland). file will be used with an endodontic motor X-Smart (Dentsply Sirona, Ballaigues, Switzerland) in removal of calcium hydroxide
Study NCT04324086 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide with Irrisafe Ultrasonic tip
Description: passive ultrasonic irrigation (PUI) with an IrriSafe Ultrasonic tips (Acteon,France), which will be driven by an ultrasonic device (Newtron P5, Satelec, Acteongroup, Merignac, France) in reemoval of calcium hydroxide
Study NCT04324086 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide with side vented needle
Description: conventional syringe irrigation with side vented needle (prime Dent, India) in removal of calcium hydroxide